August 6, 2025 — Leads & Copy — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has successfully sold its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V. (“IPA Europe”), to AVS Bio for $12 million USD.
The transaction generated $11.7 million USD in net proceeds. AVS Bio is a portfolio company of Arlington Capital Partners.
The sale supports IPA’s strategic refinement, streamlines its operations, and strengthens its balance sheet, enabling a focus on growth areas. Proceeds will fund investment in scientific platforms, data-driven discovery technologies, and expansion of strategic programs.
Dr. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies Ltd., stated the transaction delivers value to IPA and investors, reflecting a strategy to focus on the AI-based SaaS platform. A 12-month Transition Services Agreement (TSA) will ensure continuity during the transition. Edgemont Partners acted as the exclusive financial advisor to IPA.
For more information, contact
Contact:
Dr. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies Ltd.
Source: ImmunoPrecise Antibodies Ltd.
